Literature DB >> 17335902

Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.

Amir Ghaemi1, Hoorieh Soleimanjahi, Taravat Bamdad, Sara Soudi, Ehsan Arefeian, Seyed Mahmood Hashemi, Massoumeh Ebtekar.   

Abstract

Previously, we have reported that the injection of an expression vector containing Herpes simplex virus (HSV) Glycoprotein D-1 (gD-1) generated a significant antibody response in mice and protected them against HSV lethal challenge. We tested its potential to induce antibody and cell mediated immune responses in latently infected mice. Positive control group (KOS) and HSV gD-1 vaccinated mice demonstrated protection against a lethal ocularly challenge of 10(5.5) plaque-forming units (pfu)/eye of wild HSV-1 versus negative control groups. For neutralizing antibody titers, delayed-type hypersensitivity (DTH), lymphocyte proliferation responses, clinical evaluation and survival following lethal challenge, no considerable difference was observed between mice vaccinated with DNA plasmid and those vaccinated with KOS. KOS-vaccinated mice demonstrated the ability to completely prevent latency whereas DNA vaccinated group showed some degree of protection and displayed less latency than negative control groups and had considerably high levels of IFN-gamma and strong CTL responses versus negative control groups. It can be concluded that although immunization with the DNA vaccine is more effective in both protecting mice and induction of immune response, however it could not completely block the latent infection in sensory nerves.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335902     DOI: 10.1016/j.cimid.2007.01.002

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  7 in total

1.  Localization of herpes simplex virus type 1 DNA in latently infected BALB/c mice neurons using in situ polymerase chain reaction.

Authors:  Behzad Khansarinejad; Hoorieh Soleimanjahi; Amir Ghaemi; Taki Tiraihi; Shahram Pour Beiranvand
Journal:  Iran Biomed J       Date:  2010-07

2.  Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.

Authors:  Seyed Mohammad Miri; Behzad Pourhossein; Seyed Younes Hosseini; Mohsen Keshavarz; Shohreh Shahmahmoodi; Mohammad Reza Zolfaghari; Seyed Reza Mohebbi; Ali Gorji; Amir Ghaemi
Journal:  Virol J       Date:  2022-06-25       Impact factor: 5.913

3.  Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

Authors:  Malihe Naderi; Atefeh Saeedi; Abdolvahab Moradi; Mishar Kleshadi; Mohammad Reza Zolfaghari; Ali Gorji; Amir Ghaemi
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

4.  Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice.

Authors:  Zahra Gorzin; Ali Akbar Gorzin; Alijan Tabarraei; Naser Behnampour; Shiva Irani; Amir Ghaemi
Journal:  Iran Biomed J       Date:  2014

5.  Effect of oral genistein administration in early and late phases of allergic encephalomyelitis.

Authors:  Soodeh Razeghi Jahromi; Seyed Rafi Arrefhosseini; Amir Ghaemi; Akram Alizadeh; Fateme Sabetghadam; Mansoureh Togha
Journal:  Iran J Basic Med Sci       Date:  2014-07       Impact factor: 2.699

6.  Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.

Authors:  Elham Mahdevar; Amirhosein Kefayat; Ashkan Safavi; Amirhossein Behnia; Seyed Hossein Hejazi; Amaneh Javid; Fatemeh Ghahremani
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

7.  Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems.

Authors:  Alireza Tahamtan; Amir Ghaemi; Ali Gorji; Hamid R Kalhor; Azadeh Sajadian; Alijan Tabarraei; Abdolvahab Moradi; Fatemeh Atyabi; Mishar Kelishadi
Journal:  J Biomed Sci       Date:  2014-07-31       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.